EX-99 2 lazarreleaseversion2.htm CONVERTED BY EDGARWIZ

Converted by EDGARwiz

Novogen Launches Joint Venture Aimed At Developing Drugs

to Fight Ovarian Cancer

SYDNEY,   Australia   (November   7,   2013) –   Novogen   Limited   (Australian   Stock

Exchange: NRT and NASDAQ: NVGN), an Australian biotechnology company dedicated

to developing drugs that provide long-term remission through the successful control of

cancer stem cells, today announced a joint venture with Yale University dedicated to

developing personalized approaches to chemotherapy to fight ovarian cancer.

The joint venture, which will be based near Yale’s campus in New Haven, CT, will be

known as CanTx, Inc. Novogen will own 85% of the new company. Dr Graham Kelly will

be  the  CEO  of  the  new  company  and  the  Board  will  comprise  directors  from  both

Novogen and Yale.

CanTx will assume responsibility for advancing Novogen’s super-benzopyran drug

technology into the clinic for the treatment of ovarian cancer. The first product planned

on coming into the clinic in 2014 is a product to be administered intra-peritoneally to

women with ovarian cancer and designed to seek out cancer cells and deliver a payload

of a Novogen drug that has been shown to be highly cytotoxic against ovarian cancer

cells including ovarian cancer stem cells.

“There have been no new therapies for ovarian cancer in the last 30 years and a fresh

approach  is  urgently  needed,”  said  Gil  Mor,  M.D.,  Ph.D.,  Professor  of  Obstetrics  and

Gynecology and Reproductive Science at Yale University School of Medicine. “Current

chemotherapy unfortunately only does half the job. It is reasonably effective at killing

the predominant somatic cancer cells, but by not killing the cancer stem cells, the cancer

is highly likely to recur.”

Dr. Mor, who will co-lead clinical development efforts for CanTx, is the first researcher

in the world to isolate ovarian cancer stem cells, the cells responsible for the initial

growth of ovarian tumors and their recurrence following chemotherapy.

“Around 70% of ovarian patients who respond to first round chemotherapy will

eventually experience tumor recurrence,” Dr. Mor added. “Our research with the

Novogen  super-benzopyran  family  of  drugs  shows  a  high  degree  of  activity  against

ovarian cancer stem cells where no other approach has worked in our experience to

date. We believe that by combining this powerful new personalized approach with our

unique drug delivery model, we may be able to treat ovarian cancer and prevent its

recurrence.”

Dr. Mor and his team have developed an innovative targeted delivery system that allows

the entire dose of the injected drug to reach the intended target in mice. Typically, when

anti-cancer  drugs  are  injected  intravenously,  approximately  3%  of  the  drug  actually

reaches the tumor.

“This joint venture with Yale brings a level of expertise, resources and firepower that is

unique in the field of ovarian cancer,” said Graham Kelly, PhD, Chief Executive Officer,

Novogen. “This program will be the first in the world dedicated to finding an effective

treatment for ovarian cancer, with the advantage that promising treatments are capable

of being moved quickly into clinical studies in months instead of years.”

“The first product is already undergoing a standard pre-clinical development program

and our goal is to have this in the clinic in 2014.”

“However  the  longer-term  goal is to  go  one  step further  and  provide  personalized

chemotherapy, which means matching chemotherapy to the individual. To achieve this

lofty goal, you need two fundamentals: on the one hand, the ability to extract the cancer

stem cells from an individual cancer in order to assess the sensitivity of an individual

tumor to  drugs; on the other hand, to have  the drugs that can be  modified to  work

across individual tumor genotypes.”

“Yale and Novogen are uniquely positioned in having these two fundamentals. That is

why the two parties have come together and joined forces to combat this deadly

disease. Yale has  the  expertise  in cancer  stem  cells culture;  Novogen has  the  drug

technology capable of killing these tumor-initiating cells.”

Under this joint venture arrangement, Novogen retains full ownership of its drug

technology intellectual property (IP) and will grant CanTx access to that IP for drug

development purposes. Novogen will continue to explore applications of the same

technology platform in a range of other clinical indications including glioblastoma, along

with its anti-tropomyosin drug technology in the areas of prostate cancer, melanoma

and neuroblastoma.

About Ovarian Cancer

The American Cancer Society estimates that over 22,000 women will be diagnosed with

ovarian cancer during 2013 and 14,230 American women will die from the disease. It

ranks fifth in cancer deaths among women, accounting for more deaths than any other

cancer of the female reproductive system. This cancer mainly develops in older women.

About half of the women who are diagnosed with ovarian cancer are 63 years or older.

It is more common in white women that African-American women.

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade on both

the  Australian  Stock  Exchange  (symbol  ‘NRT’)  and  NASDAQ (symbol  ‘NVGN’). The

Company is based in Sydney, Australia and is focused on the development of novel anti-

cancer drugs based on two proprietary drug technologies - the super-benzopyran

chemical family and anti-tropomyosin drug technology.

About Cancer Stem Cells

Cancer   stem   cells   are   thought   to   be   the   tumor-initiating   cells   in   many   cancers

responsible for both the production of the tumor mass and metastasis. Cancer stem cells

have been confirmed in both ovarian cancers and glioblastoma. These cells are highly

resistant to chemotherapy and radiotherapy, a property thought responsible for tumor

recurrence following successful initial therapy.

Contact details

Dr Graham Kelly, Chief Executive Officer

Tel: 61 2 9476 0344

Fax: 61 2 9476 0388

Mobile: (61) 0429 854 390

16-20 Edgeworth David Ave  Hornsby  NSW  2077  AUSTRALIA

PO Box 2333 Hornsby Westfield   NSW  1635   AUSTRALIA

Email:  graham.kelly@novogen.com

Web:   www.novogen.com

Dr Graham Kelly, Chief Executive Officer

Tel: 61 2 9476 0344

Fax: 61 2 9476 0388

Mobile: (61) 0429 854 390